Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-330 in Advanced Solid Tumors and Non-Hodgkin Lymphoma
NCT06939283Phase 2Completed
- Sponsor
- Werewolf Therapeutics, Inc.
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Cytokines & Interferons, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WTX-330 in solid tumor, non-Hodgkin lymphoma (NHL), melanoma and 1 more (4 arms), sponsored by Werewolf Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Treatment Emergent Adverse Events at 24 months and 3 more. Started Apr 2025; status: completed.
02
Drugs
WTX-330
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)melanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06939283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939283.